A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The objective of this non-interventional study is to examine whether use of Phosphodiesterase
Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset
of acute NAION.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.